Cronos (CRON) Income from Non-Controlling Interests (2019 - 2026)
Cronos' (CRON) quarterly Income from Non-Controlling Interests came in at $1.1 million in Q1 2026, down 31.92% year-on-year from $1.6 million in Q1 2025, and up 3105.88% quarter-over-quarter from $34000.0 in Q4 2025.
Cronos (CRON) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Cronos' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 31.92% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $4.7 million, a 665.58% increase from a year earlier, with the FY2025 full-year figure at $6.5 million, up 716.07% from the prior year.
- Income from Non-Controlling Interests advanced to $1.1 million in Q1 2026 per CRON's latest filing, from $34000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.4 million in Q3 2025 and bottomed at -$714000.0 in Q4 2024.
- The 5-year median for Income from Non-Controlling Interests is -$8000.0 (2023), against an average of $298117.6.
- Across the five-year window, Income from Non-Controlling Interests sank 1562.5% in 2024 and surged 61550.0% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$16000.0 in 2022, then tumbled by 1381.25% to -$237000.0 in 2023, then sank by 201.27% to -$714000.0 in 2024, then soared by 104.76% to $34000.0 in 2025, then soared by 3105.88% to $1.1 million in 2026.
- Per Business Quant, the three latest CRON Income from Non-Controlling Interests figures stand at $1.1 million (Q1 2026), $34000.0 (Q4 2025), and $2.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Cronos | 1.04 Bn | 267.78 Mn | 19.15 Mn | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 34,000.00 |
| Sep 30, 2025 | 2.36 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | -714,000.00 |
| Sep 30, 2024 | -269,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -133,000.00 |
| Dec 31, 2023 | -237,000.00 |
| Sep 30, 2023 | -41,000.00 |
| Jun 30, 2023 | -137,000.00 |
| Mar 31, 2023 | -8,000.00 |
| Dec 31, 2022 | -16,000.00 |
| Sep 30, 2022 | 201,000.00 |
| Jun 30, 2022 | 122,000.00 |
| Mar 31, 2022 | -15,000.00 |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | -265,000.00 |
| Jun 30, 2021 | -394,000.00 |